Xarelto® and Uncontrollable Bleeding
The Food and Drug Administration (FDA) has recently called Xarelto’s safety into question, as various clinical trials have linked the drug to increased internal bleeding, specifically in the stomach and eyes.
According to one trial involving nearly 46,000 patients taking blood thinners, those who took Xarelto were twice as likely to experience uncontrollable stomach bleeding as compared to those taking warfarin, a blood thinner from a different class of medications.
In yet another study, elderly patients who switched from warfarin to Xarelto suffered from a condition known as vitreous hemorrhaging, which occurs when blood leaks into the space between the cornea and retina of the eye.
While certain studies have indicated elderly patients may be more susceptible to uncontrollable bleeding caused by Xarelto, hundreds of patients have died from excessive internal bleeding after taking the drug, regardless of their age.
In 2012, a report released by the FDA concluded that all patients taking Xarelto are three times more likely to die from uncontrollable bleeding as compared to patients taking warfarin.
XARELTO® is licensed from Bayer HealthCare AG